{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:47:40Z","timestamp":1790689660661,"version":"4.1.0"},"reference-count":31,"publisher":"BMJ","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"accepted":{"date-parts":[[2010,4,3]]},"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To use national laboratory surveillance data to determine whether pathogens responsible for neonatal bacteraemia were sensitive to nationally recommended antibiotic regimens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>All reports of neonatal bacteraemia received by the Health Protection Agency's voluntary surveillance scheme in England and Wales from January 2006 until March 2008, were extracted from the database. Organisms were ranked by frequency, and proportions susceptible to antimicrobials recommended for empirical treatment of neonatal sepsis were determined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 1516 reports of bacteraemia for neonates &lt;48 h old (early-onset) and 3482 reports for neonates 2\u201328 days old (late-onset). For early-onset bacteraemia, group B streptococcus (GBS) was the most frequent pathogen (31%) followed by coagulase-negative staphylococci (CoNS; 22%), non-pyogenic streptococci (9%) and <jats:italic>Escherichia coli<\/jats:italic> (9%). For late-onset bacteraemia, CoNS were isolated most frequently (45%), followed by <jats:italic>Staphylococcus aureus<\/jats:italic> (13%), Enterobacteriaceae (9%), <jats:italic>E coli<\/jats:italic> (7%) and GBS (7%). More than 94% of organisms (early-onset) were susceptible to regimens involving combinations of penicillin with either gentamicin or amoxicillin, amoxicillin combined with cefotaxime or cefotaxime monotherapy. More than 95% of organisms (late-onset) were susceptible to gentamicin with either flucloxacillin or amoxicillin and amoxicillin with cefotaxime, but only 79% were susceptible to cefotaxime monotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Current guidelines for empirical therapy in neonates with sepsis are appropriate. However, gentamicin-based regimens should be used in preference to cefotaxime-based treatments, because of lower levels of susceptibility to cefotaxime and the need to avoid exerting selective pressure for resistance. Surveillance data linked to clinical data should further inform rational antibiotic prescribing in neonatal units.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/adc.2009.178483","type":"journal-article","created":{"date-parts":[[2010,6,28]],"date-time":"2010-06-28T23:44:57Z","timestamp":1277768697000},"page":"F4-F8","source":"Crossref","is-referenced-by-count":143,"title":["Empirical treatment of neonatal sepsis: are the current guidelines adequate?"],"prefix":"10.1136","volume":"96","author":[{"given":"B","family":"Muller-Pebody","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A P","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P T","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R E","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K L","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Sharland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"iCAP Group (Improving Antibiotic Prescribing in Primary Care)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2010,6,28]]},"reference":[{"key":"2025090513372346000_96.1.F4.1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2007.126458"},{"key":"2025090513372346000_96.1.F4.2","first-page":"487","article-title":"Adverse perinatal outcome and resistant Enterobacteriaceae after antibiotic usage for premature rupture of the membranes and group B streptococcus carriage","volume":"82","author":"McDuffie","year":"1993","journal-title":"Obstet Gynecol"},{"key":"2025090513372346000_96.1.F4.3","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000168749.82105.64"},{"key":"2025090513372346000_96.1.F4.4","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200209000-00011"},{"key":"2025090513372346000_96.1.F4.5","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyh062"},{"key":"2025090513372346000_96.1.F4.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15389-5"},{"key":"2025090513372346000_96.1.F4.7","doi-asserted-by":"publisher","DOI":"10.1093\/tropej\/46.2.86"},{"key":"2025090513372346000_96.1.F4.8","doi-asserted-by":"publisher","DOI":"10.1097\/01.PCC.0000059736.20597.75"},{"key":"2025090513372346000_96.1.F4.9","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3201\/eid1109.050148","article-title":"Characterizing vancomycin-resistant enterococci in neonatal intensive care","volume":"11","author":"Sherer","year":"2005","journal-title":"Emerging Infect Dis"},{"key":"2025090513372346000_96.1.F4.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2004.03.001"},{"key":"2025090513372346000_96.1.F4.11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.760-766.2005"},{"key":"2025090513372346000_96.1.F4.12","unstructured":"The Paediatric Formulary Committee. BNF for children. British Medical Association, Royal Pharmaceutical Society of Great Britain, Royal College of Paediatrics and Child Health, Neonatal and Paediatric Pharmacists Group, 2008."},{"key":"2025090513372346000_96.1.F4.13","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm543"},{"key":"2025090513372346000_96.1.F4.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7229.213"},{"key":"2025090513372346000_96.1.F4.15","doi-asserted-by":"publisher","DOI":"10.1080\/080352598750031392"},{"key":"2025090513372346000_96.1.F4.16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.4.690"},{"key":"2025090513372346000_96.1.F4.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7477.1277"},{"key":"2025090513372346000_96.1.F4.18","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm153"},{"key":"2025090513372346000_96.1.F4.19","first-page":"1","article-title":"Prevention of perinatal group B streptococcal disease \u2013 revised guidelines from CDC","volume":"51","author":"CDC","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025090513372346000_96.1.F4.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39325.681806.AD"},{"key":"2025090513372346000_96.1.F4.21","unstructured":"RCOG Royal College of Obstetricians and Gynaecologists. Prevention of early onset neonatal group B streptococcal disease \u2013 guideline no. 36. Guidelines and Audit Committee of the RCOG. 1 November 2003, London."},{"key":"2025090513372346000_96.1.F4.22","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070477"},{"key":"2025090513372346000_96.1.F4.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2008.05.009"},{"key":"2025090513372346000_96.1.F4.24","first-page":"51","article-title":"Coagulase-negative staphylococcal bacteremia in critically ill children: risk factors and antimicrobial susceptibility","volume":"36","author":"Huang","year":"2003","journal-title":"J Microbiol Immunol Infect"},{"key":"2025090513372346000_96.1.F4.25","doi-asserted-by":"publisher","DOI":"10.1136\/fn.88.2.F89"},{"key":"2025090513372346000_96.1.F4.26","unstructured":"Gilbert DN Moellering RC Eliopoulos GM . Comparison of antimicrobial spectra. In: The Sanford guide to antimicrobial therapy 2008. Sperryville, Virginia, USA: Antimicrobial Therapy, 2008:65\u201370."},{"key":"2025090513372346000_96.1.F4.27","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1985.02140130024022"},{"key":"2025090513372346000_96.1.F4.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)90015-1"},{"key":"2025090513372346000_96.1.F4.29","doi-asserted-by":"publisher","DOI":"10.1136\/adc.62.2.148"},{"key":"2025090513372346000_96.1.F4.30","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181606850"},{"key":"2025090513372346000_96.1.F4.31","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn353"}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/adc.2009.178483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T20:37:29Z","timestamp":1757104649000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/adc.2009.178483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,28]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,12,22]]},"published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1136\/adc.2009.178483"],"URL":"https:\/\/doi.org\/10.1136\/adc.2009.178483","relation":{},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"value":"1359-2998","type":"print"},{"value":"1468-2052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,28]]}}}